Abstract
Tumor cells are not only susceptible to signals from the environment, but they likewise release signal substances. It is well known that tumor cells secrete angiogenic factors - most prominently the vascular endothelial growth factor - which initiate the vascularization of the tumor for its nourishment. This process has been termed neoangiogenesis. Besides this, two further processes have recently been discovered that facilitate the interaction of the tumor with the lymphatic system and the nervous system, named lymphangiogenesis and neoneurogenesis. These three “geneses” have a cognate, in part common regulation and conjointly promote metastasis development. Neoangiogenesis and lymphangiogenesis provide the structures for the two routes of tumor cell dissemination, i.e. either hematogenous or lymphatic. Neoneurogenesis accomplishes the innervation of the tumor by the ingrowth of nerve endings into the tumor and alternatively or additionally by the protection of existing nerve cells from destruction. These tumor-innervating nerve cells may release neurotransmitters which are proliferative or promigratory signals for the tumor cells. Furthermore, nerve fibers are used as routes for tumor cell dissemination, too, which is known as perineural invasion.
Keywords: Neoangiogenesis, lymphangiogenesis, neoneurogenesis, perineural invasion, metastasis formation
Current Pharmaceutical Design
Title: Connecting A Tumor to the Environment
Volume: 13 Issue: 33
Author(s): Frank Entschladen, Daniel Palm, Theodore L. Drell IV,, Kerstin Lang and Kurt S. Zaenker
Affiliation:
Keywords: Neoangiogenesis, lymphangiogenesis, neoneurogenesis, perineural invasion, metastasis formation
Abstract: Tumor cells are not only susceptible to signals from the environment, but they likewise release signal substances. It is well known that tumor cells secrete angiogenic factors - most prominently the vascular endothelial growth factor - which initiate the vascularization of the tumor for its nourishment. This process has been termed neoangiogenesis. Besides this, two further processes have recently been discovered that facilitate the interaction of the tumor with the lymphatic system and the nervous system, named lymphangiogenesis and neoneurogenesis. These three “geneses” have a cognate, in part common regulation and conjointly promote metastasis development. Neoangiogenesis and lymphangiogenesis provide the structures for the two routes of tumor cell dissemination, i.e. either hematogenous or lymphatic. Neoneurogenesis accomplishes the innervation of the tumor by the ingrowth of nerve endings into the tumor and alternatively or additionally by the protection of existing nerve cells from destruction. These tumor-innervating nerve cells may release neurotransmitters which are proliferative or promigratory signals for the tumor cells. Furthermore, nerve fibers are used as routes for tumor cell dissemination, too, which is known as perineural invasion.
Export Options
About this article
Cite this article as:
Entschladen Frank, Palm Daniel, Drell IV, L. Theodore, Lang Kerstin and Zaenker S. Kurt, Connecting A Tumor to the Environment, Current Pharmaceutical Design 2007; 13 (33) . https://dx.doi.org/10.2174/138161207782360573
DOI https://dx.doi.org/10.2174/138161207782360573 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Meet Our Regional Editor
Anti-Cancer Agents in Medicinal Chemistry Innovative Treatment Approach for Cancer-Related Cachexia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Hyperpolarized <sup>13</sup>C MR Angiography
Current Pharmaceutical Design Cyclin-Dependent Kinase-2 as a Target for Cancer Therapy: Progress in the Development of CDK2 Inhibitors as Anti-Cancer Agents
Current Medicinal Chemistry Inhibiting Cyclin-Dependent Kinase / Cyclin Activity for the Treatment of Cancer and Cardiovascular Disease
Current Pharmaceutical Biotechnology H+-myo-Inositol Transporter SLC2A13 as a Potential Marker for Cancer Stem Cells in an Oral Squamous Cell Carcinoma
Current Cancer Drug Targets Approaches for Imaging the Diabetic Pancreas: First Results
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Tumor Invasion and Oxidative Stress: Biomarkers and Therapeutic Strategies
Current Molecular Medicine Telomerase Modulation in Therapeutic Approach
Current Pharmaceutical Design Hypoxic Tumor Microenvironment and Cancer Cell Differentiation
Current Molecular Medicine Gene Therapy Targeting Nuclear Factor-κB: Towards Clinical Application in Inflammatory Diseases and Cancer
Current Gene Therapy HOX Genes as Potential Markers of Circulating Tumour Cells
Current Molecular Medicine TRAIL Gene Therapy: From Preclinical Development to Clinical Application
Current Gene Therapy Inhibition of Membrane Fusion as a Target for Antiviral Therapy
Anti-Infective Agents in Medicinal Chemistry DNA Repair Proteins as Molecular Targets for Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Electrochemotherapy as First Line Cancer Treatment: Experiences from Veterinary Medicine in Developing Novel Protocols
Current Cancer Drug Targets NOX3-Targeted Therapies for Inner Ear Pathologies
Current Pharmaceutical Design Targeting Metabolic Enzymes in Cancer – Clinical Trials Update
Current Enzyme Inhibition Carbon Monoxide in Renal Physiology, Pathogenesis and Treatment of Renal Disease
Current Pharmaceutical Design Linkage of Stress with Neuromuscular Disorders
CNS & Neurological Disorders - Drug Targets